2026-10-12T00:08:04Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34040571 2026-10-01T07:00:04Z category_37339 category_37351 category_37363 category_37366 portal_1012 item_type_6 month_year_10_2026

Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL) Polly Niravath (15052941) Ann C. Anselme (8851325) Ivonne Uzair (24228287) Kai Sun (15052938) Hanh Mai (24228290) Jian Guan (24228293) Mailin Li (24228296) Jenying Deng (24228299) Wei Qian (24228302) Jianying Zhou (24228305) Liliana Guzman (24228308) Kelsey Banaglorioso (24228311) Rabia Hashmani (24228314) Sunil Mathur (15052959) Jenny Chang (24228317) Cancer Tumor Biology Immuno-oncology Clinical Research and Trials Breast Cancer Clinical Trial Results Immunotherapy Tumor Microenvironment Cytokines and the microenvironment Immune cells and the microenvironment <p>Supplementary Table 2: Representativeness of Study Participants</p> 2026-05-01T00:00:00Z Text Journal contribution 10.1158/1078-0432.34040571 https://figshare.com/articles/journal_contribution/Supplementary_Table_S2_from_A_Phase_II_Study_of_Docetaxel_and_Pembrolizumab_plus_Interleukin_12_Gene_Therapy_in_Nonmetastatic_Anthracycline-Refractory_Triple-Negative_Breast_Cancer_INTEGRAL_/34040571 CC BY